Pediatric Precision Medicine Cancer Care Summit (MPD24006)

Pediatric Precision Cancer
March 22 - 23, 2024
Grand Hyatt San Francisco
San Francisco, CA
Course# MPD24006

March 22 - 23, 2024
Grand Hyatt San Francisco
San Francisco, CA
Course# MPD24006
Department: Pediatrics/Center for Cancer, Blood Disorders and Cellular Therapy

Register Today

COVID-19 Guidelines

 

Registration Fees

Physicians $550.00

Advanced Practice Professionals $400.00

Residents/Fellows $400.00

Cancellation Policy

Cancellations received in writing before March 7, 2024 will be refunded, less a $100 administrative fee. No refunds will be made on cancellations received after that date.

Please email your requests to [email protected]

 

Overview

SAVE THE DATE

Mark your calendar to join your colleagues at the Pediatric Precision Cancer Medicine Summit.

Grand Hyatt San Francisco
San Francisco - March 22-23, 2024

The summit brings together leading experts to discuss the latest breakthroughs in precision medicine and how these advances are changing the landscape of pediatric cancer care, research and precision-based oncology.

CME credits will be available.

More details to come, check back soon. Course outline can be viewed below.


Target audience: Physicians, Nurse Practitioners, Physician Assistants, Nurses, Clinical Geneticists, PhD Researchers, Laboratory Professionals

 

Objectives

  • Articulate the significance of recent advances in liquid biopsies, demonstrating their application in measuring minimal residual disease and early detection of relapse.
  • Investigate and appraise new therapeutic opportunities for patients in the relapsed setting using next-generation sequencing panels, while critically assessing the limitations of this technology.
  • Analyze and differentiate the frequency and diversity of germline alterations relevant to cancer diagnosis in children and young adults.
  • Apply knowledge of germline alterations to implement precise screening practices for patients with cancer and their families.
  • Evaluate and address current barriers impeding the widespread use of immunotherapy in pediatric cancer.
  • Recognize and assess the emerging importance of CART and other cell therapies in pediatric cancer.

 

Accreditation

In support of improving patient care, the University of California, San Francisco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Course Outline

Friday, March 22, 2024
7:00 AM Registration and Breakfast  
7:45 Welcome and Overview Alejandro Sweet-Cordero, MD 
UCSF Benioff Children’s Hospitals 
    John Maris, MD
Children’s Hospital of Philadelphia
Session A:  Next Generation Diagnostics
8:00 Cancer Gene Panel Testing in Pediatric Populations: The UCSF Experience  Jessica Van Ziffle, PhD, FACMG
UCSF
8:30 Liquid Biopsy for Neuroblastoma Lea Surrey, MD
Children’s Hospital of Philadelphia
9:00 Towards Mapping Drug Resistance Heritability in Pediatric ALL Charles Gawad, MD, PhD
Stanford University
9:30 Coffee Break  
9:45 Integrated Analysis of Methylation and Transcription in Pediatric AML  Benjamin Huang, MD
UCSF Benioff Children’s Hospitals
10:15 Advances in the Molecular Pathogenesis of Pediatric Brain Tumors David Solomon, MD, PhD
UCSF
Session B:  Clinical Trials
10:45 Leveraging International Collaborations to Improve Outcomes in JMML Elliot Stieglitz, MD
UCSF Benioff Children’s Hospitals
11:15 Precision Medicine for Rare Pediatric Cancers: Lessons Learned and Future Directions Ted Laetsch, MD
Children's Hospital of Philadelphia
11:45 LUNCH  
1:00 An International, Multi-disciplinary, and Multi-faceted Approach to Advancing Precision-based Care for Pediatric CNS Tumors Cassie Kline, MD, MAS
Children's Hospital of Philadelphia
1:30 PM Multi-pronged Precision Approaches to Target the ALK Oncoprotein. Yael Mossé, MD
Children's Hospital of Philadelphia
     
2:00 Biopharma Approaches to Targeted Drug Therapy Development in Pediatric Oncology Mark Kieran, MD, PhD
Day One Bio
2:30 Coffee Break  
Session C: Non-Catalytic Oncogenic Targeting
2:45 Targeting Oncogenic N-myc Complexes in High-risk Pediatric Neural Tumors Bo Qiu, MD, PhD
UCSF Benioff Children’s Hospitals
3:15 Targeting Translational Control of PAX3-FOXO1 Amit J. Sabnis, MD 
UCSF Benioff Children’s Hospitals
3:45 Targeted Protein Degradation of Pediatric Oncoproteins: Strategies and Progress Gwenn Hansen, PhD
Nurix
4:15 Coffee Break  
4:30 Understanding the Pathogenesis and Developing Therapeutics for Fibrolamellar Carcinoma Sanford M. Simon, PhD
Rockefeller University; The Fibrolamellar Registry
5:00 Targeting Intracellular Proteins through MHC 1 for Cancer Applications Charles Craik, MD
UCSF
5:30 Pax3:Foxo1 Targeting Genetically and Via Multiple Pharmacological Approaches for Clinical Investigation Charles Keller, MD
Children's Cancer Therapy Development Institute
6:00 PM Adjourn  
Saturday, March 23, 2023
7:00 AM Breakfast  
Session D:  Cancer Predisposition
8:00 Replication Repair Deficiency in Brain Tumors: Linking Causes with Therapy Uri Tabori, MD
The Hospital for Sick Children
8:30 COG ACNS0333: Lessons Learned from the First Cooperative Group ATRT Trial  Alyssa T. Reddy, MD
UCSF Benioff Children's Hospital 
9:00 The Diagnosis and Long-term Care of Children with a Hereditary Predisposition to Cancer.   Nicola Cadenas, MD
UCSF Benioff Children’s Hospitals
9:30 Coffee Break  
9:45 Unraveling the Genetic Basis of Neuroblastoma: Recent Findings, Future Directions, and Translational Opportunities Sharon Diskin, PhD
Children's Hospital of Philadelphia
10:15 Risk Stratification to Personalize Therapy for Neurofibromatosis Type 1-Associated Tumors Chelsea Kotch, MD MSCE
Children’s Hospital of Philadelphia
10:45 Coffee Break  
Session E: Immunotherapies
11:00 Novel Strategies of Targeting Tumor Antigens In Adult and Pediatric Glioma Hideho Okada, MD, PhD
UCSF
11:30 Proteomic Strategies to Uncover Cellular Therapy Targets for Refractory Pediatric Hematologic Malignancies Arun Wiita, MD
UCSF
12:00 PM Developing GPC2-directed Immunotherapies for Pediatric Cancers Kristopher Bosse, MD
Children's Hospital of Philadelphia
12:30 LUNCH  
1:45 CAR T Cell Therapy for CNS Malignancies Jessica Foster, MD
Children’s Hospital of Philadelphia
2:15 Leveraging Real-world Data to Advance Immunotherapy Outcomes Liora Schultz, MD
Stanford University
2:45 Closing Remarks Alejandro Sweet-Cordero, MD 
UCSF Benioff Children’s Hospitals 
    John Maris, MD
Children’s Hospital of Philadelphia 
3:00 PM Adjourn   

 

Course Chairs

Alejandro Sweet-Cordero, MD
UCSF Benioff Children’s Hospitals
Professor of Pediatrics

Joey Mack
UCSF Benioff Children’s Hospitals
Service Line Director, CCBDCT

John M. Maris, MD
Children’s Hospital of Philadelphia
Giulio D'Angio Professor of Pediatric Oncology
Perelman School of Medicine at the University of Pennsylvania

 

 

 

UCSF Faculty

Nicola Cadenas, MD
Charles Craik, PhD
Benjamin Huang, MD
Bo Qiu, MD, PhD
Alyssa T. Reddy, MD
Amit J. Sabnis, MD
David Solomon, MD, PhD
Elliot Stieglitz, MD
Jessica Van Ziffle, PhD, FACMG

Guest Faculty

Kristopher Bosse, MD
Sharon Diskin, PhD
Jessica Foster, MD
Charles Gawad, MD, PhD
Gwenn Hansen, PhD
Charles Keller, MD
Mark Kieran, MD, PhD
Cassie Kline, MD, MAS
Chelsea Kotch, MD, MSCE
Theodore W. Laetsch, MD
Yael Mosse, MD
Hideho Okada, MD, PhD
Liora Schultz, MD
Sanford Simon, PhD
Lea Surrey, MD
Uri Tabori, MD
Arun Wiita, MD, PhD

 

Travel & Lodging

Grand Hyatt San Francisco
345 Stockton Street
San Francisco, CA 94108

Online Reservations Available Here

The last day to reserve the rooms at the group rate is on February 29th

UNITED AIRLINES
UCSF has negotiated special fares with United Airlines for our course attendees. Download Online Booking Instructions (.pdf)
Code ZMGE963115

 


Exhibitors

Exhibit Fee: $TBA
Email Contact for Exhibits  [email protected]

Exhibit Description

Exhibitors receive the following benefits:

  • (1) 6’ x 30” tabletop exhibit space at UCSF assigned location in exhibit hall
  • Standard acknowledgement from the podium
  • Acknowledgement in the course syllabus distributed to each registrant*
  • (2) complimentary exhibitor attendees and (1) copy of the course syllabus

Exhibit Hours

(subject to updating)

EXHIBIT HOURS (subject to updating)

March 22, 2024  
7:00- 8:00AM Exhibit Area open during Registration
9:30- 10:30AM Coffee Break in Exhibit Area
3:00- 3:30PM Coffee Break in Exhibit Area
March 23, 2024  
7:00- 8:00AM Continental Breakfast in Exhibit Area
9:30- 10:30AM Coffee Break in Exhibit Area
3:00- 3:30PM Coffee Break in Exhibit Area